Stock Screener App

Frei -

Installieren

3.345

7.08% -0.255

Newcelx Ltd (NCEL)

Überblick Nachrichten Preisverlauf Forum Prognose

Newcelx Ltd Aktie (NCEL) Neueste Nachrichten

NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria

Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo

NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative

NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et

NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey

NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

NewcelX Ord Shs (NCEL) Income Statement - TradingKey

NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey

NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey

NewcelX Ord Shs (NCEL) Cash Flow - TradingKey

NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView

NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times

NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et

Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo

NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus

Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com

NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks

NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times

NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang

NewcelX Appoints Diabetes Research Leader Camillo Ricordi to Scientific Advisory Board Following FDA Pre-IND Milestone - Quiver Quantitative

Enterprise value to EBIT forward of NewcelX Ltd. – BOATS:NCEL - TradingView

Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView

Enterprise value to EBITDA forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView

NCELNewcelX Ltd Volatility & Greeks - Finviz

NewcelX Ltd. (NCEL) Holds Steady at $3.85 as Traders Eye Key ResistanceInsider Buying Alerts - dars.gov.et

Price to book forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView

NCEL Should I Buy - Intellectia AI

Newcelx Announces Successful FDA Pre-Ind Meet - Moomoo

NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - theglobeandmail.com

NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - The Manila Times

NewcelX receives FDA feedback on type 1 diabetes therapy plan By Investing.com - Investing.com India

NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative

NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com

NewcelX Ltd. (NCEL) Gains 2.72%: Approaching Key Resistance at $3.96IPO Entry Watch - po-news-eg.net

NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks

Number of shareholders of NewcelX Ltd. – NASDAQ:NCEL - TradingView

Number of shareholders of NewcelX Ltd. – BOATS:NCEL - TradingView

NewcelX Ltd. Actuals & Estimates (NASDAQ:NCEL) - TradingView

NewcelX Ord Shs (NCEL) Institutional Confidence - TradingKey

[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan

NewcelX Ord Shs (NCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN

NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis - TipRanks

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - The Manila Times

MRNA

$63.32

0.52%

RPRX

$58.60

0.07%

ROIV

$36.20

0.22%

INSM

$123.74

2.05%

ALNY

$228.65

0.67%

ONC

$347.48

2.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters